Toll‐like receptor‐mediated IRE1α activation as a therapeutic target for inflammatory arthritis by Qiu, Quan et al.
Toll-like receptor-mediated IRE1 activation as a therapeutic target for 
inflammatory arthritis 
 
 
Quan Qiu1, Ze Zheng2, Lin Chang9, Yuan-Si Zhao3, Can Tan1, Aditya Dandekar5, Jenney Z. Zhang4, 
Zhenghong Lin1, Ming Gui1, Xiu Li7，Tongshuai Zhang7, Qingfei Kong1,7, Hulun Li7, Sha Chen8, An Chen8, 
Randal J. Kaufman10, William Yang11, Hui-Kuan Lin11, Donna Zhang12, Harris Perlman12, Edward Thorp1, 
Kezhong Zhang2,5 # and Deyu Fang1,4 #  
 
 
Supplemental files: 
 
1. Supplemental Materials & Methods 
2. Supplemental Table 1 
3. Supplemental figures 1-15 and their legends. 
4. Unprocessed images of all figures and supplemental figures.   
Supplemental Materials and Methods (Qiu et al)  
Cells and Reagents. Human endothelial kidney (HEK) 293 cells were maintained in Dulbecco's 
Modification of Eagle's Medium (Cellgro, Mediatech, MA, USA) containing 10% fetal calf serum 
(GIBCO, Invitrogen, Grand Island, NE, USA). Transfection in HEK 293T cells was performed with 
Lipofectamine™ 2000 protocol (Invitrogen, Grand Island, NE, USA). Mouse RAW 264.7 cells were also 
cultured in 10% FCS-containing D-MEM. Wild-type and TRAF6 knockout MEF cells were cultured as 
previously reported (Yang et al, 2009). Plasmids expressing IRE1 and its truncated mutants were 
generated by PCR using linker primers and sub-cloned into pCMV-Flag vector (Sigma-Aldrich, St. Louis, 
MO, USA). Myc-tagged TRAF6 expression plasmid and its C70A mutant were used as reported (Yang et 
al, 2009).  The truncated mutants were generated by PCR with linker primers followed by sub-cloning 
into pCMV-Myc vector (Invitrogen, Grand Island, NE, USA). lipopolysaccharide (LPS) and  
polyinosinic–polycytidylic acid potassium salt (poly(I:C)) were purchased from Sigma-Aldrich. 
Tripalmitoyl cysteinyl seryl tetralysine lipopeptide (Pam3CSK4) was purchased from InvivoGen (San 
Diego, CA, USA). Tunicamycin was purchased from Enzo (Farmingdale, USA). The resources of 
antibodies are as the following: IRE1phosph-eIF2α (Cell Signaling, Danvers, MA, USA); ATF6 
(abcam, Cambridge, MA, USA);  Flag, -actin, and Tubulin (Sigma-Aldrich); c-Myc and HA (Santa Cruz 
Biotech, Santa Cruz, CA, USA); TRAF6 (Prosci, Poway, CA USA); PP2A (BD Bioscience, San Diego, 
CA, USA) and all the antibodies against the cell surface molecules for flow cytometry (Biolegend, San 
Diego, CA, USA). The IRE1 inhibitor 4U8C was purchased from Ryan Scientific (Mount Pleasant, SC, 
USA). 
Isolation of RNA from human synovial macrophages. Synovial fluids from RA and OA patients were 
cultivated in the 6-well plate for 2 hours. Adherent cells were collected and lyszed by Trizol and the total 
RNA was isolated. 
Mice. The IRE1flox/flox mice were generated as previously described 29. The IRE1flox/flox mice were 
backcrossed with C57BL/6J mice for over 10 generations to maintain the C57BL strain background. The 
myeloid-specific IRE1 knockout mice were generated by crossing IRE1flox/flox mice with transgenic 
mice expressing Cre under the control of the lysozyme M (LysM) gene promoter (LysM-Cre). LysM-Cre 
transgenic mice were purchased from Jackson laboratory. All mice used in this study were maintained and 
used at the Northwestern University mouse facility under pathogen-free conditions according to 
institutional guidelines and animal study proposals approved by the institutional animal care and use 
committees. 
Transfection, co-immunoprecipitation and western blotting analysis. Transient transfection of HEK 
293T cells was performed by using Lipofectamine 2000 (Invitrogen), according to the manufacturer’s 
instructions. Two days after transfection, cells were lysed in Nonidet P-40 lysis buffer (1%Nonidet P-40, 
20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, and freshly added protease inhibitor cocktails). 
The cell lysates were incubated with an antibody (1 g) for 2 hr on ice, followed by the addition of 30 L 
of fast-flow protein G-Sepharose beads (GE Healthcare Bioscience, Uppsala, Sweden) overnight at 4 °C. 
Immunoprecipitates were washed four times with NP-40 lysis buffer and boiled in 30 L of 2× Laemmli 
buffer.  Samples were subjected to 8% or 10% SDS-PAGE analysis and electrotransferred onto 
nitrocellulose membranes (0.45M; Bio-Rad). Membranes were probed with the indicated primary 
antibodies, followed by horseradish peroxidase-conjugated secondary antibodies. Membranes were then 
washed and visualized with an enhanced chemiluminescence detection system (Bio-Rad, Hercules, CA, 
USA). When necessary membranes were stripped by incubation in stripping buffer (Thermo, Rockford, 
MA, USA), washed, and then reprobed with other antibodies as indicated.  
RNA isolation and quantitative real-time RT-PCR. Total RNA was extracted with TRIzol (Invitrogen) 
and cDNA was synthesized using the cDNA synthesis kit (qScript™ cDNA Synthesis Kit; Quanta). 
SYBR Green fluorescent reagent and a MyiQ™2 two-color real-time detection system (Bio-Rad) were 
used for quantitative real-time RT-PCR. The relative amount of mRNA was calculated by the 
comparative threshold cycle method withβactin as a control. The amplification efficiencies of all the 
primers were estimated by classical calibration dilution curve and slope calculation. For all housekeeping 
and target genes assessed, standard curves were evaluated on 10-fold serial dilutions of control bone 
marrow derived macrophage cDNA to determine reaction efficiency. Specificity of primer pairs were 
evaluated by using both no-RT and water template control samples. Primer sequences are shown in the 
supplementary Table 1.  
Flow cytometry analysis. Single-cell suspensions of thymi and secondary lymphoid organs were 
obtained by mincing the organs through a cell strainer dish. Primary cells or bone marrow derived 
macrophages were washed in FACS buffer (PBS/3%FBS), and stained according to standard procedures 
with the antibodies that specifically against each of the cell surface molecules including CD11b, CD11c, 
F4/80, MHC II, CD4, CD8, B220, IgM, CD206, Gr-1, FcRI (Biolegend, San Diego, CA, USA), and 
TLRs (eBioscience, San Diego, CA, USA). Intracellular staining of TNF- (Biolegend, San Diego, CA, 
USA) was performed according to the protocol from eBioscience instructions. Flow cytometry was 
performed on a BD FACSCanto or Accuri C6 flow cytometery (BD Biosciences, San Diego, CA, USA). 
The data were analyzed using flowjo software excluding cell doublets. For analyzing apoptosis, the 
Annexin-V antibody (BD Biosciences) was used according to the manufacturer’s protocol. 
Histology. Tissue samples were prepared by fixing tissue 24-48 hr in 10% neutral buffered Formalin 
(VWR, West Chester, PA, USA). Fixed joints were decalcified by treatment with Decalcifying solution 
(Thermo, Rockford, MA, USA) for 24 hr. Samples were then washed with PBS, dehydrated with a series 
of ethanol washes (50% ethanol, followed by 70% ethanol), and embedded in paraffin. Sections of 4 m 
were stained with H&E or preceded to immunohistochemical staining. Representative sections from 
individual mice within groups of 5-10 mice were selected to illustrate the general state of each group’s 
ankle joints. Antibodies were purchased from the following companies: anti-Myeloperoxidase and anti- 
Tryptase (abcam, Cambridge, MA, USA); anti-MAC3 (BD Biosciences, San Diego, CA, USA); and 
secondary anti-rat IgG or anti-rabbit IgG (Vector laboratories, Burlingame, CA, USA).  
Pulse chase assay for IRE1 protein synthesis and degradation. Mouse embryonic fibroblasts (MEFs) 
(1 ×10
6
) were cultured for 24 hours before adding the methionine/cysteine-free media with 
35
S-
Methionine/Cysteine (100 ci/ml). After 2-4 hours of culture, the supernatant was changed to normal 
media and samples were collect at different time intervals for the following immunoprecipitation assays 
with the anti-IRE1α antibody.  
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Supplementary Figure Legends 
Supplementary Table 1.  
Sequences of all primers used in this study are shown in the Supplementary Table 1. 
Supplementary Fig. 1. Purity of the samples from RA and OA patients. Adherent cells from patients 
fluids were collect and analyzed by flow cytometry, the percentage of CD11b
+ 
single positive cells (A) or 
CD11b
+
CD206
+
 double positive cells (B) from RA (n=3) or OA (n=3) patient samples is shown. (C) The 
patient information was summarized and RA patients were grouped by their disease phase (acute vs 
chronic). The average XBP-1s levels are indicated. Student t-test was used for the statistic analysis, 
*p<0.05, **p<0.01, ***p<0.005.  Iso, isotype controls. 
Supplementary Fig. 2. Characterization of IRE1 gene deletion in macrophages. (A) T cells (CD3+), 
B cells (B220
+
) and macrophage (F4/80
+
 CD11b
+
) from the spleens of IRE1 conditional knockout 
(IRE1flox/flox LysM-Cre+) mice and their littermate controls (IRE1+/+ LysM-Cre+) were sorted. IRE1 
protein expression levels were analyzed by western blotting (top panel) using -actin as a loading control. 
(B) Thioglycollated elicited macrophage (F4/80
+
 CD11b
high
) were sorted from wild-type and mutant mice, 
the IRE1 protein expression was analyzed by western blotting as described in (A). (C & D) Peritoneal 
cells were isolated from wild-type and mutant mice. The F4/80
+ 
CD11b
+
 macrophages were sorted and 
stimulated with TM (5g/ml) for 16 hr. The mRNA levels of unspliced XBP-1 and spliced XBP-1 were 
determined by semi-quantitative RT-PCR (C) or quantitative real-time RT-PCR (D).  
Supplementary Fig. 3. The expression of CXCR2, CCR9, CD16 and CD5aR in myeloid cells from 
the wild-type and IRE1f/f LysM-Cre+ mice. Wild-type and mutant mice were injected (I.P) with 150l 
K/BxN serum, 6 days after injection, macrophage (CD11b
+
F4/80
+
), neutrophils (CD11b
+
Gr-1
+
) and mast 
cells (CD117
+
FcRI+) from peritoneal cavity, spleen and peripheral blood were collected for flow 
cytometry analysis, representative data from independent experiments was shown. Solid lines indicate 
wild-type (WT), dotted lines indicate knockout (KO) cells. 
Supplementary Fig. 4. Analysis of macrophages in the wild-type and IRE1f/f LysM-Cre+ mice.  (A) 
Cells from the spleen (Spl, left panels) and peripheral lymph nodes (pLN, right panels) of IRE1f/f LysM-
Cre
-
 and IRE1f/f LysM-Cre+ mice were isolated. The macrophages were characterized by their cell 
surface expression of CD11b and F4/80. (B) The bone marrow-derived macrophages from IRE1f/f LysM-
Cre
-
 and IRE1f/f LysM-Cre+ mice were analyzed for their cell surface expression of CD11b, F4/80, MHC 
II and CD11c. 
Supplementary Fig. 5. The development of immune cells in IRE1 conditional knockout mice. (A & 
B) Thymocytes were isolated from the wild-type and IRE1f/f LysM-Cre+ mice and stained with 
fluorescence-conjugated antibodies against CD4, CD8, CD25 and CD44. Cells were then analyzed for 
their expression of CD4 and CD8 (A). The CD4 and CD8 double negative cells were gated and their 
expression levels of CD44 and CD25 were analyzed (B). (C-E & G) Cells from the spleens of the wild-
type and IRE1f/f LysM-Cre+ mice were isolated and stained with antibodies against each cell surface 
markers as indicated and analyzed by flow cytometry. The percentages of CD4 and CD8-positive cells are 
shown (C, left panels). The expression levels of CD44 and CD62L of the gated CD4
+
 (C, middle panels) 
or CD8
+
 T cells were analyzed (C, right panels). CD4
+
 T cells from thymus or spleen were gated and the 
percentages of Tregs were determined by intracellular staining of FoxP3 and their cell surface expression 
of CD25 (D). The percentages of NK and NKT cells (E) were analyzed by NK1.1 and CD3 expression. 
DC subsets were analyzed by CD11c expression (F). (G) Bone marrow cells were isolated and the 
development of B cells was analyzed with anti-B220 and anti-IgM antibodies. 
Supplementary Fig. 6. TLRs expression and apoptosis analysis of macrophages from wild-type and 
IRE1αf/fLysM-Cre+ mice. (A) Bone marrow-derived macrophages from wild-type and mutant mice were 
stimulated with LPS (100 ng/ml), Pam3 (100 ng/ml), or poly(I:C) (10 g/ml) for 24hr. The apoptotic 
subset of F4/80
+
 CD11b
+
 cells was analyzed by by Annexin Ⅴ and PI staining. (B) The bone marrow-
derived macrophages from IRE1f/fLysM-Cre- and IRE1f/fLysM-Cre+ mice were analyzed for their 
expression of TLR2, TLR3 and TLR4 using specific antibodies or isotype controls (iso). 
Supplementary Fig. 7. Characterization of neutrophils in IRE1-deficient mice. (A) The percentage 
of spleen neutrophils (CD11b
+
 Gr-1
+
) and mast cells (CD117
+
FcR+) in the spleens from wild-type and 
mutant mice are shown. (B & C) Anti-GPI serum (200l/mouse) was intraperitoneally injected into wild-
type and mutant mice. At 16 hr after the injection, peritoneal cavity cells were isolated. The absolute cell 
number (B) and distribution of neutrophils (CD11b
+
Gr-1
+
) were measured by flow cytometry (C). (D) 
The isolated cells were further stimulated in vitro with LPS (1 g/ml) for 3hr, TNF- secretion was 
measured by flow cytometry. Representative images are shown. The percentages represent data from 
three pairs of mice. Student t-test was used for the statistic analysis, *p<0.05, **p<0.01, ***p<0.005. 
Supplementary Fig. 8. Analysis of IRE1 activation in macrophages induced by TNF-. (A & B) 
Bone marrow derived macrophages from ERAI mice were stimulated with LPS (100 ng/ml), Pam3 (100 
ng/ml), polyI:C (10 g/ml), TNF- (20 ng/ml), or TM (5 g/ml) for indicated time intervals. The GPF 
expression level (A) and mean fluorescence intensity (B) was measured by flow cytometry. (C) 
RAW264.7 (Mouse leukaemic monocyte macrophage cell line) cells were stimulated TNF- (20 ng/ml) 
for the indicated time. The activation of IRE1 (phosph-IRE1) was determined by phos-tag gel assay. 
Supplementary Fig. 9. Reconstitution of IRE1α functions in the IRE1–null cells with IRE1 
mutants or with XBP-1s.  WT and IRE1-null MEFs were infected with control adenovirus or with that 
expresses IRE1 or it mutant (kinase-negative mutant, KM; RNase-negative mutant, RM) (A) or with 
XBP-1s (B). Cells were cultured for three days, re-plated onto 6-well plates and cultured in fresh media. 
Infected cells were then stimulated with or without LPS for 4 hours and the mRNA levels of IL-6 were 
determined by quantitative real-time PCR. Error bars represent data from a tri-placated study and the 
representative data from three experiments are shown.  
Supplementary Fig. 10. Analysis of the regulated IRE1-dependent decay (RIDD) upon TLR 
response. Bone marrow-derived macrophages from wild-type and IRE1 mutant mice were stimulated 
with LPS (100ng/ml), Pam3 (100ng/ml), or polyI:C (10g/ml) for 6h. The mRNA levels of RIDD genes 
(Blos1, Hgnat, Pmp22, Scara3, Col6 and PdgfR) were determined by quantitative real-time RT-PCR 
(qPCR). Error bars represent the SDs in qPCR replicates; representative data from two independent 
experiments are shown. 
Supplementary Fig. 11. Analysis of ER stress signaling in the response to LPS. (A) Wild-type and 
IRE1-null BMMs were stimulated with LPS (1 g/ml) for 30 minutes or 24 hr, the levels of activated 
JNK (phosph-JNK) (top panel), total JNK (2
nd
 panel), phosph-p38 (3
rd
 panel), phosph-ERK1/2 (4
th
 panel), 
and total Erk1/2 (5
th
 panel) were analyzed by western blotting using specific antibodies. Tubulin level was 
determined as a loading control (bottom panel). The gene targeting of IRE1 in cells were also confirmed 
by western blotting (6
th
 panel). (B) The levels of ER stress related proteins, including IRE1, phosph-
EIF2, ATF6, and cleaved ATF6, were analyzed by western blotting. 
Supplementary Fig. 12. Activation of IRE1 in MEFs under the stimulation of LPS. Wild-type and 
TRAF6-null MEF cells were stimulated with LPS (100ng/ml) for 16hr. The levels of spliced XBP-1 
mRNA were measured by quantitative real-time RT-PCR.    
Supplementary Fig. 13. Glucose or serum regulates the interaction between PP2A and IRE1. (A) 
Wild-type and TRAF6 knockout MEF cells were cultured with glucose/serum-free media or normal media 
for 4 hours. Binging of PP2A to IRE1 was determined by immunoprecipitation with the anti-PP2A 
antibody (top panel). The expression levels of PP2A, IRE1 and TRAF6 in whole cell lysates were 
determined by western blotting analysis. (B) The intensities of IRE1 bands that interacted with PP2A 
were quantified. The relative band intensities are shown.  
Supplementary Fig. 14. Analysis of IRE1 protein stability in cells upon LPS stimulation. (A) RAW 
cells were treated with 100 g/ml cycloheximide (CHX) for the indicated time intervals in the presence or 
absence of LPS (1g/ml). The protein levels of IRE1 (top panel) and tubulin (bottom panel) in the 
lysates of treated cells were examined by western blotting analysis. (B) RAW cells were pulsed with 
35
S-
methionine for 4 hour. At the different time intervals indicated, LPS (1g/ml) was added into the cell 
culture media. The IRE1 protein levels were measured by immunoprecipitation with the anti-IRE1 
antibody. (C & D) RAW cells were stimulated with LPS for the indicated time points. (C) The IRE1 
protein levels were detected by western blotting (top panel) using -Actin as a control (bottom panel). (D) 
The band densities was quantified and normalized against the loading control-Actin. Representitive data 
from three independent experiments are shown.
 
 (E & F) 
35
S-methionine pulse chase analysis to measure 
the synthesis and degradation of IRE1 protein in MEF cells. Wild-type and TRAF6- null MEF cells were 
pulsed with 
35
S-methionine media for 2 hours, and then the media was replaced with normal media. The 
samples were collected at the different time intervals indicated. The IRE1 protein levels were measured 
by immunoprecipitation with the anti-IRE1 antibody. The relative band intensities are shown in (F). 
Supplementary Fig. 15. Expression level of PP2A in wild-type and TRAF6-null MEFs. Cell lysates of 
wild-type and TRAF6 knockout MEFs were subjected to western blotting analysis of PP2A protein 
expression levels (top panel). TRAF6 gene targeting in the MEFs was confirmed (middle panel). Actin 
levels were determined as loading controls (bottom panel). 
 
 
 
 
 
 
 
  
Gene Forward Reverse 
RT-PCR Xbp1 ACACGCTTGGGAATGGACAC CCATGGGAAGATGTTCTGGG 
Q-PCR IRE1α GGGTTGCTGTCGTGCCTCGAG TGGGGGCCTTCCAGCAAAGGA 
Xbp-1 ACACGCTTGGGAATGGACAC CCATGGGAAGATGTTCTGGG 
Xbp-1s GAGTCCGCAGCAGGTG GTGTCAGAGTCCATGGGA 
IL-6 ACCTGTCTATACCACTTCACAAGT TCTGCAAGTGCATCATCGTTGTTC 
IL1-β CAACCAACAAGTGATATTCTCCATG GATCCACACTCTCCAGCTGCA 
TNF-α CCAGACCCTCACACTCAGATC AGTTGGTTGTCTTTGAGATCCATG 
ISG15 AGCGGAACAAGTCACGAAGAC TGGGGCTTTAGGCCATACTC 
Rantes GCCTACCTCTCCCTCGCGCT GGTTGGCACACACTTGGCGG 
IFN-β TCCAGCTCCAAGAAAGGACG GCATCTTCTCCGTCATCTCC 
Supplementary Table 1.  Primers used in this study. 
 
Diseases      Patient number     Gender (M/F)      Age             XBP-1s      
RA/acute               13                        2/11               43+16          512+203 
RA/chronic             8                          1/7                51+18          487+195 
OA (all acute)         7                          4/3                46+19          229+126            
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